STEPHEN MENENDEZ: Open Payments
NPI 1962052407 · HAMMOND, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$749 in 40 payments from 14 companies in 2025. Trend: 2023 $712 · 2024 $559 · 2025 $749
Food & beverage: $749
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $173 |
| E.R. Squibb & Sons, L.L.C. | 4 | $82 |
| Janssen Pharmaceuticals, Inc | 4 | $78 |
| Otsuka America Pharmaceutical, Inc. | 4 | $77 |
| Indivior Inc. | 3 | $56 |
| Neurocrine BioSciences, Inc. | 2 | $49 |
| Teva Pharmaceuticals USA, Inc. | 2 | $46 |
| Supernus Pharmaceuticals, Inc. | 1 | $45 |
| Vanda Pharmaceuticals Inc. | 1 | $39 |
| Lundbeck LLC | 1 | $27 |
Products named: CAPLYTA, COBENFY, ABILIFY ASIMTUFII, SUBLOCADE, INVEGA SUSTENNA, INGREZZA, REXULTI, Qelbree.
Industry payments across LA — which companies pay providers there.
